Filter By Category
Archives
Share on -
ATIGLIFLOZIN
Generic Name: ATIGLIFLOZIN
ABSTRACT -
Atigliflozin (AVE-2268) is a substituted glycopyranoside small-molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor. It was investigated as an antihyperglycemic agent for type 2 diabetes by promoting urinary glucose excretion and reducing blood glucose. Public development information indicates that it reached clinical evaluation but was not widely approved for routine use.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved standard dosing regimen is established for routine public use.
- Clinical-trial dosing must follow the protocol, renal-function criteria, and glucose-monitoring plan.
- Do not combine with other antidiabetic medicines without medical supervision.
SIDE EFFECTS–
Possible side effects and safety concerns include:
- Increased urination, thirst, dizziness, or dehydration
- Genital or urinary tract infections
- Nausea, abdominal discomfort, or fatigue
- Changes in kidney function or electrolytes may occur
- Rare but serious ketoacidosis-like events are a class concern for SGLT2 inhibitors.
ALLERGIC REACTIONS -
Hypersensitivity to Atigliflozin or related compounds/products may occur. Symptoms may include:
- Immediate urticaria or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing or breathing difficulty
- Dizziness, collapse, or anaphylaxis
Important: Patients who develop an allergic reaction to Atigliflozin should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Atigliflozin may interact with certain medicines, protocols, vaccines, clinical conditions, or procedures. Caution is needed with:
- Insulin or insulin secretagogues may increase hypoglycemia risk when combined with glucose-lowering agents.
- Diuretics may increase dehydration or low blood pressure risk.
- Renal impairment can alter benefit and safety monitoring.
- Other investigational antidiabetic therapies require protocol review.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Assess kidney function, hydration status, and diabetes control before use.
- Monitor for symptoms of ketoacidosis even if glucose is not very high.
- Use caution in patients with recurrent urinary/genital infections.
- Pregnancy and lactation use should follow specialist advice.
WARNINGS –
- Not a substitute for diet, exercise, and individualized diabetes care.
- Stop and seek urgent care for ketoacidosis symptoms such as vomiting, abdominal pain, rapid breathing, or confusion.
- Avoid use during serious acute illness unless directed by a clinician.
- Keep out of reach of children.
Share on -
. Developed by